Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta
Authors:
- Juan L. GarciaJGJuan L. Garcia
- Jaime Font de MoraJMJaime Font de Mora
- Jesus M. HernandezJesus M. Hernandez
- Jose A. QueizanJQJose A. Queizan
- Norma C. GutierrezNorma C. Gutierrez
- Jose M. HernandezJHJose M. Hernandez
- Jesus F. San MiguelJMJesus F. San Miguel
- 1 October 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 102 (7) , 2699-2700
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic SyndromeNew England Journal of Medicine, 2003
- Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor β receptor fusion oncogeneBlood, 2002
- Glivec (STI571, imatinib), a rationally developed, targeted anticancer drugNature Reviews Drug Discovery, 2002
- H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor β gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22)Blood, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemiaAnnals of Oncology, 2000